Arsenic bioaccessibility tests are now being commonly used in risk assessment. However, 12 concerns remain about the reliability of such tests because the bioaccessibility of arsenic 13 from soil may be susceptible to soil composition (including iron concentration), as well as 14 method considerations such as varying liquid-to-solid ratios and the chosen buffer system. 15
INTRODUCTION 7 8
Traditional human health risk estimates are based on the total concentration of 9 contaminants in soils, [1, 2] but several regulatory bodies worldwide now recognize that this 10 may overestimate the actual risk. [3] [4] [5] Instead, using the bioavailable fraction, or the fraction 11 of a substance that can be absorbed and reach systemic circulation, [6] may provide a more 12 representative estimation. This is especially important when the bioavailable fraction is 13 potentially much smaller than the total concentration of a contaminant. Such is the case for 14 arsenic in soils, which is considered only one-fifth as bioavailable as soluble (aqueous) 15 inorganic arsenic. [7] 16 17 Arsenic bioavailability data may be obtained by measuring arsenic concentrations in the 18 blood and tissues of animals following their ingestion of arsenic-contaminated substrates. 19 Several in vivo ingestion studies have indicated that arsenic soil bioavailability depends on 20 soil type and contaminant source, and varies from 2 to 48%. [8] [9] [10] [11] [12] Because bioavailability 21 varies greatly, site and soil-specific measurements are required.
1
Although the use of in vivo models may provide representative bioavailability data for 2 estimating risks, the costs and ethics of using these models has led to the development of 3 laboratory-based in vitro extraction tests that simulate human in vivo conditions. Results 4 from these tests provide an estimation of bioaccessibility, which is defined as the fraction 5 of a substance that is soluble in the gastrointestinal environment and is available for 6 absorption. [13] Several methods have been developed to assess the bioaccessibility of soil 7 contaminants but the results vary between methods, and concerns remain regarding the 8 reliability of such measurements. 9 10 Ruby et al. [11, 14] published one of the first studies examining a physiologically-based 11 extraction test (PBET). This test was based on rabbit gastrointestinal conditions and is 12 similar to paediatric conditions. It takes into consideration gastric and intestinal chemistry, 13 extraction pH, soil mass and fluid volume, stomach mixing and emptying rate, and small 14 intestinal transit time. This test is considered to be a valid predictor of oral lead 15 bioaccessibility. [15, 16] Rodriguez et al. [17] indicated that the arsenic bioaccessibility data 16 obtained by such an in vitro gastric method is strongly correlated with in vivo 17 bioavailability results, although the test slightly underestimated bioavailability. Several 18 additional studies have used variations of this physiologically-based method to measure the 19 bioaccessibility of metals, or to simplify the method. [17] [18] [19] 20 21 Parallel method development has been carried out by various agencies including the 1 Solubility/Bioavailability Research Consortium (SBRC), which has established a simple in 2 vitro test using glycine as a buffer. [20] The SBRC calls for 0.4 M glycine, which is a much 3 higher concentration than the < 1 mM concentrations of glycine typically found in 4 biological fluids.
[21] Although not physiologically representative, the gastric phase of the 5 SBRC method -also entitled the Relative Bioaccessibility Leaching Procedure -has been 6 validated against in vivo lead bioavailability data. [22] The USEPA recommends this method 7
to determine the relative bioavailability of lead for the purposes of risk assessment in 8
Region 8 (Colorado Area). [23] The in vivo database for arsenic is not as extensive as that 9 for lead, [20] and a glycine-buffered test has yet to be validated for estimating arsenic 10 bioavailability. [24] 11 12
In addition to the inherent variability introduced by any chosen method and their related 13 parameters (e.g. extraction pH, liquid-to-solid ratios), the bioaccessibility of arsenic may 14 be affected by arsenic speciation [25] and soil physicochemical properties. Specifically, 15 higher soil iron oxide content and lower soil pH both tend to yield lower 16 bioaccessibility. [26] [27] [28] In some cases, the bioaccessibility is negatively correlated with 17 arsenic concentration in soil, [25, 29] but other studies have found the bioaccessibility of 18 arsenic to be independent of soil arsenic concentration. [19] The negative dependence of 19 bioaccessibility on soil arsenic concentration may be an indication of solubility saturation, 20
and Richardson et al. [30] recommend carrying out tests at various liquid-to-solid ratios to 21 rule out this possibility. In some cases (where glycine was used as a buffer), the arsenic 22 bioaccessibility increased with an increased ratio, [31] whereas other studies (that did not use 1 glycine) have shown arsenic bioaccessibility to be independent of liquid-to-solid ratio. [25] 2 Thus the choice of buffer in estimating arsenic bioaccessibility may influence the results. 3
4
In this study, arsenic-contaminated tailings, soils and reference materials representing a 5 range of iron to arsenic molar ratios were subjected to bioaccessibility tests using both a 6 physiologically-based test (Method P) and a glycine-buffered test (Method G) under 7 simulated gastric and gastric followed by intestinal conditions. The results were examined 8 to determine the effects of extraction pH, liquid-to-solid ratio, buffer choice and 9 concentration, and arsenic and iron concentrations on the bioaccessibility of arsenic. The 10 objective was to evaluate the variability introduced by the methods and sample 11 characteristics in measuring the bioaccessibility of arsenic. The test materials consisted of soils and tailings samples, reference materials, and solid 18 matrices. The soils and tailings samples were taken from arsenic-contaminated abandoned 19 gold mine sites in Nova Scotia, Canada, [32] and are described by Meunier et al. [25] The 20 standard reference materials selected were NIST2710 [33] and NIST2711 [34] , and a reference 21 soil from the British Geological Survey (BGS 102) was also tested.
[35] Two more samples 22 consisted primarily of arsenic minerals: a mine tailings sample rich in scorodite 1 (FeAsO 4 •2H 2 O) collected at Lower Seal Harbour (LSH), Nova Scotia, Canada, [32] and a 2 sample of arsenopyrite (FeAsS) from Niñas de Panasqueira, Portugal (Ward's Natural 3 Science). Ironite® (Mineral Supplement 1-0-0), a commercial fertilizer that contains high 4 concentrations of arsenic and iron from mine waste was also tested. All tailings samples 5 were dried and sieved to a <150 μm particle size. The arsenopyrite and LSH tailings 6 samples were ground and homogenized, using a mortar and pestle, to a <150 μm particle 7 size. Ironite® was sieved to <150 μm. Reference materials and soil were used as received 8
(the particle size for NIST2710 and NIST2711 is <74 μm, and the BGS102 particle size is 9 <50μm). 10 11 Sample Elemental Composition 12
13
The certified arsenic and iron concentrations of the standard reference materials NIST2710 14 and 2711 were used. [33, 34] All other samples were analyzed for major and trace elements by 15 aqua regia digestion. Analytical results for the Nova Scotia samples are described in detail 16 by Parsons et al. [32] Digestions of the remaining samples were performed according to 17
Method 200.7 [36] and analyzed by the Analytical Services Unit, Queen's university, 18
Kingston, ON using inductively coupled plasma-optical emission spectrometry (Varian 19 AX-Vista Pro). The results for the total arsenic concentration in BGS102 (94 mg•kg -1 ) is 20 comparable to unpublished data for this sample (102 mg•kg -1 ).
[37] For each sample, the bioaccessibility of arsenic and iron was measured using two different 3 methods and two liquid-to-solid ratios (i.e. 100:1 and 2000:1). The glycine-buffered 4
Method G was based on a SBRC method modified from Kelley et al.
[20] The 5 physiologically-based Method P was modified from Ruby et al. [11] and Rodriguez et al., [17] 6 and is similar to tests carried out by Cave et al. [38] and Koch et al. [39] These in vitro 7 experiments consisted of a gastric phase (phase 1, denoted P1), and a gastric followed by 8 an intestinal phase (phase 2, denoted P2). 9 10 Experiments were carried out in batches of 8 to 12 samples, along with two duplicate pairs, 11 one blank and one reference material (NIST2710 or NIST2711) for each phase. All 12 chemicals and reagents used in the bioaccessibility tests were analytical grade or better, 13 and all solutions were prepared with distilled deionised water (DDW, Barnstead E-pure 14 reverse osmosis/ion exchange apparatus Water Purification System, minimum resistance 15 18 MΩ•cm). 16 17 Gastric solution compositions are described in detail by Koch et al. [39] . Briefly, the gastric 18 [39]
The solution was similarly acidified to a pH of 1.80 ± 0.05. 3 4 Test procedures are identical for both methods. In the 100:1 liquid-to-solid ratio tests, two 5 subsamples were tested for each sample (representing P1 and P2). Measured amounts of 6 gastric solution (20 ml) were poured into 50-ml polyethylene specimen containers and 7 heated to 37 °C. A previously measured quantity of solid sample (0.2 g) was added to this 8 prepared solution and the test containers were secured in a temperature-controlled flatbed 9 rotation incubator (New Brunswick Scientific Innova 4230) at 37 °C and 150 rpm under 10 aerobic conditions. The pH was measured after 30 minutes (and acidified as required), and 11 again at the end of the one-hour gastric phase. Samples were stirred over a hot plate (37 12 °C) while pH measurement took place, and the time taken to measure pH (less than six 13 minutes per sample) was included in the overall incubation time. At the end of the gastric 14 stage of the test, samples used in the gastric phase only (P1) were removed from the 15 sample set. 16
17
The remaining samples were retained for the gastric followed by intestinal phase of the test 18 (denoted P2). At the beginning of P2, the solutions were modified to simulate intestinal 19 conditions by raising the pH to 7.0  0.2 using a saturated NaOH (Sigma-Aldrich) solution 20
for Method G, [20] and a 10 M solution of Na 2 CO 3 (Fluka) for Method P. Porcine bile 21 (Sigma) and porcine pancreatin (Sigma-Aldrich) was also added to all intestinal solutions.
Test containers were returned to the incubator. The pH was measured after two hours (and 1 adjusted as required), and again at the end of the four-hour intestinal stage of the test. The 2 time taken to measure pH (less than 12 minutes during the intestinal stage of the test) was 3 included in the overall incubation time. 4 
5
In the 2000:1 liquid-to-solid ratios tests, a single subsample was prepared for each solid 6 sample (to be used for both P1 and P2). Measured amounts of gastric solution (300 ml) 7
were poured into 1-L polyethylene specimen containers and heated to 37 ºC. A previously 8 measured quantity of solid sample (0.15 g) was added to this prepared solution. Test 9 containers were heated and shaken, and the pH was measured and adjusted as described iron results were within laboratory control limits (Table 1) . Given the low variability in 18 SRM iron bioaccessibility between all methods and all liquid-to-solid ratios, these results 19
were combined and are shown as a single entry in Table 1 ) and iron to arsenic molar ratios (from 1.2 to 2600). Of these, the 13 7
Nova Scotia tailings samples (identified by the prefixes CAR-, GD-, MG-, and NB-) were 8 included in a previous study investigating the effects of soil composition and mineralogy 9 on arsenic bioaccessibility from a suite of 29 tailings and soil samples.
[25] These 13 10 samples represent the wide range of arsenic concentrations and physical characteristics 11 encountered throughout the Nova Scotia gold mining districts. They were selected for 12 further experiments in the present study to compare the results previously obtained using 13 Method P (at the 100:1 and 2000:1 liquid-to-solid ratios) with the arsenic bioaccessibility 14 values obtained by Method G. The results of both methods are presented in Table 2  15 (arsenic bioaccessibility), and Table 3 The ease with which pH is measured and maintained throughout a bioaccessibility test can 8 be an important factor in designing a test that is simple and economical, while providing a 9 representative measure of the soluble fraction of a contaminant.
[41] Buffers that are 10 effective at gastric (pH < 2) and intestinal (pH ~ 7) pH are desirable. Glycine (used in 11
Method G, pK a s 2.3 and 9.6), as well as the combination of citrate, malate and acetate 12 (used in Method P, pK a s 3-3.4, 5-6.4) meet this requirement, since the solutions are 13 diprotic with pK a s near the appropriate pHs. [41]
These tests thereby provide more 9 conservative (protective) adjustments in human health risk assessments. Since the 10 bioaccessibility of arsenic may be influenced by the extraction pH, [11] bioaccessibility tests 11 were carried out under both gastric (acidic pH) and intestinal (neutral pH) conditions. In 12 more than 70 percent of the results (all methods tested), the bioaccessibility of arsenic is 13 greater in P2 compared to P1 (Table 2) . Inspection of the results in Table 2 reveals that  14 several tailings samples (NB11A, NB6B, GD2, LSH Tailings, CAR 1, and GD1) returned 15 a higher arsenic bioaccessibility result in P2 for all 5 treatments. The Ironite® and 16 NIST2710 sample exhibited the reverse trend of having a higher P1 arsenic 17 bioaccessibility in all cases. For the lower 100:1 liquid-to-solid ratios, variations between 18 P1 and P2 were relatively small (paired t-tests, log e transformed data, p > 0.52), but these 19 variations were statistically significant when the higher 2000:1 liquid-to-solid ratio was 20 used (paired t-tests, log e transformed data, p < 0.011) for both Methods G and P (Table 2 ). (Table 3 ). In four of the five treatments, statistical analysis reveals that the extraction pH 1 did not significantly affect the bioaccessibility of iron (paired t-tests, log e transformed data, 2 p > 0.064). The only exception is for Method G at the 100:1 liquid-to-solid ratio, where the 3 P1 results were greater than the P2 iron bioaccessibility for all but one sample (paired t-4 tests, log e transformed data, p = 0.009). 5 6 For this type of experiment, we have determined that the acceptable within-laboratory 7 repeatability is ±30%, which is consistent with the uncertainty estimated for total arsenic 8 concentration results from accredited laboratories [42] for such environmental samples. 9
Therefore, two results that are within 30% of each other are no more distinguishable than 10 two replicate analyses. The 30% uncertainty was used as a benchmark for comparison of 11 P1 and P2 values in Tables 2 and 3 Previous arsenic bioaccessibility results reveal that, for the 13 Nova Scotia mine tailings 6 samples included in the present study, Method P was insensitive to liquid-to-solid ratios 7 ranging from 100:1 to 5000:1.
[25] To test the effects of this variable, bioaccessibility 8 extractions were carried out on an additional six samples (Table 2 ). There were no 9 significant differences between the two liquid-to-solid ratios tested by Method P (paired t-10 tests, log e transformed data, p = 0.74 for the entire set of 19 samples, and p = 0.37 when 11 comparing only the six additional samples). This finding is consistent with other results 12 from physiologically-based bioaccessibility tests. [43, 44] The results are illustrated Figure 1,  13 where similarities between the two liquid-to-solid ratios are apparent for Method P, with 14 exceptions noted only for samples BGS102 and NIST2710 (higher arsenic bioaccessibility 15 at the higher liquid-to-solid ratio) and GD5 (higher arsenic bioaccessibility at the lower 16 liquid-to-solid ratio). In such a case, the bioaccessibility results obtained at the 100:1 17 liquid-to-solid ratio with Method P would be used for risk assessment purposes. [30] 18
Conversely, large variations were observed in the case of Method G (Figure 1 ). Compared 19 with the 100:1 liquid-to-solid ratio, the arsenic bioaccessibility results were significantly 20 higher when the higher 2000:1H (0.4 M glycine) ratio was used (paired t-tests, log eto-solid ratio should be retained. [30] However at this 2000:1 H liquid-to-solid ratio, a 1 greater amount of buffer is available, and we hypothesize that the buffer concentration may 2 affect arsenic bioaccessibility. bioaccessibility may result from glycine stabilizing cationic species in solution, including 5 iron (as described by Castillo and Ramirez), [45] and arsenic associated with this iron may 6 be released (i.e. when iron remains in solution, so does arsenic). Therefore, in the Method 7 G experiments, it is likely the amount of glycine present and the influence of a glycine-iron 8 complex that affects the arsenic bioaccessibility, rather than variations in the liquid-to-solid 9 ratios. In the following section, the relationship between iron and arsenic is further 10 examined by comparing bioaccessibility results and iron to arsenic concentrations. 11
12

Effect of Iron Concentration on the Bioaccessibility of Arsenic 13 14
The arsenic bioaccessibility results presented in Figure 1 are shown in decreasing order of 15 iron to arsenic molar ratio for each sample, and the results appear generally lower as this 16 ratio decreases, although this trend is not statistically significant (linear regression, r < 17 0.23, p > 0.19). However, for all five treatments, the percent arsenic bioaccessibility is 18 negatively correlated with the total arsenic concentration (linear regression, r > 0.50, p < 19 0.033) and with the total iron concentration (linear regression, r > 0.49, p < 0.035). This is 20 consistent with previous findings for similar tailings samples. [25, 29] As demonstrated in the 21 previous sections, this negative relationship is not associated with solution saturation.
Previous findings have established that the highest arsenic concentrations in the tailings 1 samples are associated with sparingly soluble arsenic minerals, [25] and the decreased 2 bioaccessibility is likely associated with an increased proportion of these minerals. 2). While this slope (0.13) is not significantly different from zero (p = 0.36), it is higher 8 than that for the other four treatments (slopes < 0.073, r < 0.32, p > 0.51). Thus, when a 9
higher liquid-to-solid ratio is used with a 0.4 M glycine concentration, higher bioaccessible 10 arsenic concentrations appear to be associated to the greatest extent with higher 11 bioaccessible iron concentrations. This result supports the hypothesis that extraction in the 12 presence of greater amounts of glycine is conducive to solubilising more iron (and 13 associated arsenic) than amounts that would be extracted under more physiologically 14 representative conditions. 15
CONCLUSION 17 18
For the series of soils and tailings studied, the bioaccessibility of arsenic estimated by 19
Method P is not significantly affected by varying solid-to-liquid ratios and changes in pH, 20 whereas differences in bioaccessibility results were observed for the glycine-buffered 21 of glycine was available in solution, which may be influenced by the interaction between 1 glycine and iron. The consequence is that using a glycine buffer in arsenic bioaccessibility 2 extractions may unduly influence the results by introducing methodological artefacts that 3 do not mimic the human gastro-intestinal conditions. At this time, neither Method P nor 4
Method G has been accepted by any regulatory agency as a validated method for arsenic 5 (against in vivo bioavailability data), [46] although some comparisons between Method G 6 and modified Method P arsenic bioaccessibility results with bioavailability results are 7 available
[47, 48 and other references therein, 49] . In vivo hamster arsenic data [50] are also available for 8 one of the samples in the present study (Ironite®). For this sample, results from all 9 methods tested (28-32% for Method P; 25-39% for Method G) compared equally well with 10 arsenic bioavailability values (31 ± 6%) and did not vary significantly between methods. 11
For this reason, it is not possible to unambiguously distinguish between methods based on 12 in vivo data; clearly more bioavailability data are required to compare and validate 13 bioaccessibility methods. 14 15
The present study demonstrates that the practicality of a method and the potential for 16 artefacts resulting from that same method must be balanced. Method G has been accepted 17 as a useful method to estimate lead bioaccessibility, and hence bioavailability, but its 18 application to other elements and soil samples may require careful consideration and study. 19 The choice of a bioaccessibility method that is both physiologically based and robust with 20 respect to changes in method variables, such as Method P, may provide more 
